UroGen Pharma Ltd.
URGN
$9.87
-$0.27-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.88% | -58.46% | 29.13% | -3.46% | -24.10% |
| Total Depreciation and Amortization | 62.42% | 15.04% | 1.14% | -25.07% | -17.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -60.65% | 50.89% | -19.47% | 67.26% | -21.07% |
| Change in Net Operating Assets | -111.90% | 261.85% | -447.43% | 173.38% | -149.70% |
| Cash from Operations | -208.57% | 50.77% | -16.49% | 25.17% | -144.19% |
| Capital Expenditure | 61.74% | -19.79% | -14.29% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -142.67% | 156.95% | -982.75% | -10.62% | 219.76% |
| Cash from Investing | -142.83% | 156.79% | -989.73% | -11.24% | 219.16% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -52.11% | -99.53% | -81.48% | 49.38% | 136,542.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | -52.11% | -99.82% | -60.51% | 83.48% | 136,542.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -244.36% | 149.65% | -207.09% | 142.96% | 249.96% |